Avillion
Pharmaceutical co-development and financing company that partners with pharma and biotech companies to accelerate and fund drug development programs through innovative risk-sharing models.
Notes
Avillion is a London-based pharmaceutical co-development company that provides a unique model for drug development partnerships. The company partners with pharmaceutical and biotechnology companies to share the risk and cost of clinical development, providing both capital and operational expertise to advance drug programs through regulatory approval.
Avillion's innovative financing model allows pharma partners to maintain optionality while accessing non-dilutive capital and development capabilities, making it an attractive partner for companies looking to advance their pipelines efficiently.
Team
- Paul Sheridan - CEO and Managing Partner
- Caroline Lynch - Chief Operating Officer
- Julie Sinnamon - Chair
Additional Research Findings
- Part of Abingworth portfolio
- Innovative co-development and risk-sharing model
- Partners with both large pharma and biotech companies
- Provides non-dilutive financing for clinical development
- Focus on advancing programs through Phase 3 and regulatory approval
- London headquarters with global partnerships
- Track record of successful drug development partnerships
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |